<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00154739</url>
  </required_header>
  <id_info>
    <org_study_id>46S1</org_study_id>
    <nct_id>NCT00154739</nct_id>
  </id_info>
  <brief_title>Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Phase II Randomized Trial of Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin in Stage IIIB/IV Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of gemcitabine/cisplatin versus
      gemcitabine/epirubicin in Stage IIIB/IV NSCLC in terms of response rate and overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most patients suffered from nausea, vomiting and prolonged anorexia after cisplatin
      treatment. Epirubicin is an anthracycline that was used widely in the treatment of cancer.
      Our previous study of an epirubicin and paclitaxel combination in non-small cell lung cancer
      patients showed a response rate of 52.6% and good median survival. However, most patients
      suffered from paclitaxel-related neurotoxicity.

      Chemotherapy may increase an average of 1 to 2 months of median survival in inoperable
      non-small cell lung cancer patients treated with chemotherapy. However, chemotherapy may not
      provide a cure for these patients. Reduction of side effects and enhancement of life quality
      of the patients are as important as life prolongation for these patients. We designed a
      combination chemotherapy using gemcitabine with epirubicin in the treatment of inoperable
      non-small cell lung cancer. The treatment will be compared to gemcitabine and cisplatin
      combination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to explore efficacy of gemcitabine and epirubicin in the treatment of NSCLC patients who need palliative chemotherapy.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objective of this study is to compare efficacy (response rateï¼Œoverall survival) of gemcitabine/epirubicin to gemcitabine/cisplatin in the treatment of inoperable NSCLC.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of stage IIIB/IV NSCLC

          -  No prior chemotherapy

          -  Age &gt; 18 years

          -  ECOG score &lt; 0 to 2

          -  Bi-dimensionally measurable lesions

          -  WBC &gt; 4,000/ml, ANC &gt; 1,500/ml, platelets&gt;100,000/ml

          -  Hb&gt;10g/dl.

          -  ALT/AST &lt; 5 times x UNL, bilirubin &lt; 1.5times x UNL, creatinine &lt; 1.25 times x UNL,
             normal calcium level

          -  Life expectancy &gt; 12 weeks

        Exclusion Criteria:

          -  CNS metastases, Concomitant myelosuppressive radiotherapy, C/T, hormonal therapy or
             immunotherapy.

          -  Active congestive heart failure, angina and/or arrhythmia requiring therapy or
             previous myocardial infarction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chin-Hsin Yang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann-Lii Cheng, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>August 1, 2008</last_update_submitted>
  <last_update_submitted_qc>August 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2008</last_update_posted>
  <keyword>Combination, Chemotherapy,non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

